ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic\u00ae TurbiLatex product for the ADVIA\u00ae Chemistry XPT System from Siemens Healthineers. This is ViroGates\u2019 first validation of the suPARnostic\u00ae TurbiLatex product for a Siemens Healthineers instrument. Siemens Healthineers is one of the leading players in the global\u00a0 in-vitro diagnostics market. ViroGates\u2019 suPARnostic\u00ae TurbiLatex product can now be implemented in clinical routine use at hospitals using the ADVIA XPT systems. The ADVIA XPT is one of the automated clinical chemistry analysers placed in laboratories at the hospitals.\u00a0 The system can run up to 2,400 samples per hour and work as a fully automated system, requiring no manual handling from the blood sampling until results are processed. The approval of suPARnostic\u00ae TurbiLatex for the ADVIA XPT platform complements the previous approvals for the Roche Diagnostics cobas systems. The suPARnostic\u00ae TurbiLatex product is based on a technology called turbidimetry, that measures the loss of intensity of transmitted light due to the scattering effect of particles suspended in the blood sample. suPARnostic\u00ae TurbiLatex is a particle-enhanced turbidimetric assay. The principle of measuring blood samples by using turbidimetry is important in relation to immunoassays. It is the basis of almost all central laboratory clinical chemistry instrument platforms in hospitals.